Essex Bio-Technology (HK:1061) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Essex Bio-Technology Limited has announced that its subsidiary has received approval to commercialize its preservative-free unit-dose Sodium Hyaluronate Eye Drops (0.3%) in the People’s Republic of China. The product is designed to treat a variety of ocular diseases and symptoms, providing a new preservative-free treatment option for conditions like dry eye syndrome. This marks a significant step for the company in expanding its portfolio of ophthalmic products in the Chinese market.
For further insights into HK:1061 stock, check out TipRanks’ Stock Analysis page.